Nutrition in liver cirrhosis: a case-based overview
Published in Frontline Gastroenterology
Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression.
Published in Gut
Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.
Published in Gut
Gut microbiota and Toll-like receptors set the stage for cytokine-mediated failure of antibacterial responses in the fib...
Published in Gut
Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensat...
Published in Gut
Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
...Published in Gut
Angiotensin II (AngII) activates via angiotensin-II-type-I receptor (AT1R) Janus-kinase-2 (JAK2)/Arhgef1 pathway and subsequently RHOA/Rho-kinase (ROCK), which induces experimental and probably human liver fibrosis. This study investigated the relationship of JAK2 to experimental and human portal hypertension. The mRNA and protein levels of JAK2/AR...
Virtual touch quantification (VTq) elastography for non-invasive assessment of liver disease and its complications: what...
Published in Frontline gastroenterology
Liver stiffness measurement (LSM) is the most widely used non-invasive alternative to biopsy for assessing liver fibrosis in the UK. Virtual touch quantification (VTq, also known as acoustic radiation force impulse) is the principal available alternative to transient elastography (Fibroscan) and is delivered via software enhancements to standard ul...
Economic study of the value of expanding HCV treatment capacity in Germany.
Published in BMJ open gastroenterology
Today's highly efficacious, low-toxicity interferon-free treatment regimens for chronic hepatitis C virus (HCV) can cure most patients with HCV in 12-24 weeks. The aim of this study was to understand how the introduction of shorter duration treatment regimens for HCV will impact the capacity for treatment and value to society. A Markov model of HCV...
Gut microbiome and liver diseases.
Published in Gut
The gut microbiota has recently evolved as a new important player in the pathophysiology of many intestinal and extraintestinal diseases. The liver is the organ which is in closest contact with the intestinal tract, and is exposed to a substantial amount of bacterial components and metabolites. Various liver disorders such as alcoholic liver diseas...
A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular c...
...Published in Gut
This work highlights the unique transcriptional niche of stellate cells, and identifies potential stellate cell targets for tracking, targeting and isolation. Hepatic stellate cell signature expression may identify patients with HCV cirrhosis or postresection HCC with poor prognosis.
